Warning letter is first issued by US FDA’s Office of Prescription Drug Promotion in more than a year and only the seventh since March 2020, continuing a trend away from using the enforcement tool. AstraZeneca asked to distribute corrective communications about pamphlet’s efficacy claims.

Webpages misrepresent findings in two clinical studies to overstate efficacy of the Cushing’s syndrome drug and minimize serious risks, Office of Prescription Drug Promotion says. This is second untitled letter issued to Xeris in three years.

Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.

US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.